Basics Altimmune, Inc. Altimmune Inc is a clinical stage immunotherapeutic biotechnology company. It is involved in the business of developing products that engage, stimulate and improve immune responses for the prevention and treatment of diseases. IPO Date: May 22, 2017 Sector: Healthcare Industry: Biotech Market Cap: $435.11M Activated in VL: True Average Daily Range Avg Daily Range: $0.30 | 4.10% Avg Daily Range (30 D): $0.08 | 2.03% Avg Daily Range (90 D): $0.09 | 2.33% Institutional Daily Volume Avg Daily Volume: 1.84M Avg Daily Volume (30 D): 2.75M Avg Daily Volume (90 D): 2.74M Trade Size Avg Trade Size (Sh.): 160 Avg Trade Size (Sh.) (30 D): 201 Avg Trade Size (Sh.) (90 D): 201 Institutional Trades Total Inst.Trades: 1,479 Avg Inst. Trade: $1.72M Avg Inst. Trade (30 D): $1.44M Avg Inst. Trade (90 D): $1.24M Avg Inst. Trade Volume: .19M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.94M Avg Closing Trade (30 D): $.77M Avg Closing Trade (90 D): $.86M Avg Closing Volume: 223.92K     News Oct 31, 2025 @ 4:00 PM Biodefense Market to Attain USD 32.87 Billion by 2... Source: Towards Healthcare Oct 6, 2025 @ 3:40 AM ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investig... Source: James (Josh) Wilson Oct 5, 2025 @ 4:00 PM ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman ... Source: Bronstein, Gewirtz & Grossman Llc Oct 4, 2025 @ 12:02 AM ALT FINAL DEADLINE: ROSEN, A GLOBAL AND LEADING FI... Source: Rosen Law Firm Oct 2, 2025 @ 11:58 AM ALT Investors Have Opportunity to Lead Altimmune, ... Source: Prnewswire Financials   TTM Q2 2025 Q1 2025 Basic EPS $-.21 $-.27 $-.26 Diluted EPS $-.21 $-.27 $-.26 Revenue $ .01M $ .01M $ .01M Gross Profit $ $ $ Net Income / Loss $ -19.01M $ -22.15M $ -19.58M Operating Income / Loss $ -20.86M $ -22.92M $ -21.82M Cost of Revenue $ $ $ Net Cash Flow $ -121.87M $ 134M $ 12.18M PE Ratio     Splits Sep 14, 2018:   1:30 May 05, 2017:   1:10 May 04, 2017:   1:10 Jul 25, 2007:   1:50